BIOLUM
Biocentre Lunaret Montpellier

IRIM
Institut de Recherche en Infectiologie de Montpellier

Cemipai

igmm
INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER

CRBM
Centre de Recherche en Biologie Cellulaire de Montpellier

Annual Symposium of the Infection & Immunity Axis - 05/02/2026

Amphithéatre Balard, 1919 route de Mende, Montpellier

Interferons in health and disease

Pre-programme



8h40-8h45 **Introduction**

8h45-9h15 **Lucile Espert, IRIM, BIOLuM**
Autophagy dampens the innate immune response during the first steps of CD4+ T lymphocytes infection by HIV-1

9h15-9h30 BIOLuM selected short talk 1

9h30-10h **Nicolas Bidère, Inserm, Nantes**
CYLD proteolysis by Caspase-3, a checkpoint to balance inflammation during mitochondrial apoptosis

10h-10h15 BIOLuM selected short talk 2

10h15-10h45 **Antoine Rebendenne (Caroline Goujons's team), IRIM, BIOLuM**
Deciphering the interferon-induced antiviral state against RNA viruses in physiologically-pertinent models of primary airway epithelia

10h45-11h05 **Coffee break (& Visit to the sponsors' booths)**

11h10-11h40 **Philippe Pasero, IGH, Montpellier**
Signaling DNA replication stress beyond cell boundaries

11h40-11h55 **Sponsor's short talks**

12h-13h **Keynote: Ben Hale**, Institut für Medizinische Virologie, Zurich University
Autoantibodies targeting interferons in human disease

13h-13h55 **Lunch buffet (& Visit to the sponsors' booths)**

14h-14h30 **Guillaume Bossis, IGMM, BIOLuM, Montpellier**
SUMOylation controls interferon-dependent anti-leukemic immune response

14h30-14h45 BIOLuM selected short talk 3

14h45-15h15 **Roger J Eloiflin (Nadine Laguette's team), IGMM, BIOLuM**
Single stranded DNA sensing is associated with activation of inflammatory and DNA damage responses

15h15-15h30 BIOLuM selected short talk 4

15h30-16h **Céline Gongora, IRCM, Montpellier**
STING-ATF3/type I IFN crosstalk: A potential target to improve anti-tumor immunity in chemotherapy-treated urothelial carcinoma

16h-16h15 **Coffee break (& Visit to the sponsors' booths)**

16h15-16h45 **Monsef Benkirane, IGH, Montpellier**
cGAS-nucleosome interactome: Bridging epigenetics, genome organization and innate immunity

16h45-17h BIOLuM selected short talk 5

17h-17h30 **Julie Constanzo, IRCM, Montpellier**
Role of extracellular vesicle in antitumor immunity



17h30-17h45 BIOLuM selected short talk 6

17h45-18h15 **Eloi Verrier, Strasbourg University**
The complex interplay between HDV and the innate immune response

18h15 **End of the symposium Drinks**

Organizing committee
Caroline Goujon
Nadine Laguette
Olivier Moncorgé
Isabelle Vila

SPONSORS

Cemipai

BioLuM
Biocentre Lunaret Montpellier

Smartlife Biosciences

InvivoGen

Biosketches of Invited Speakers
based outside Montpellier

Ben Hale completed his PhD in Molecular Virology under the supervision of Rick Randall at the University of St. Andrews, Scotland, and was a post-doctoral scientist with Adolfo Garcia-Sastre at the Mount Sinai School of Medicine, New York, USA. In 2011, he started his own research group at the MRC-University of Glasgow Centre for Virus Research, Scotland, and in 2015 relocated to the University of Zurich, Switzerland, where he is currently Full Professor of Medical Virology. Ben's research has mainly focused on studying the molecular biology of human pathogenic respiratory RNA viruses (e.g. influenza viruses), and in particular how virus-encoded virulence factors manipulate host cell defences. In recent years, however, his group has expanded its interests into further understanding the interferon (IFN) cytokine system. Beyond fundamental studies, his group has been actively developing a molecular and clinically-associated programme to study infectious disease severity associated with IFN system deficiencies, in particular with respect to the development and consequences of human autoantibodies that bind and neutralise IFNs



Nicolas Bidère earned his PhD from the Paris-Saclay University, where he focused on programmed cell death in human T lymphocytes. He then joined Mike Lenardo's laboratory at the NIH for a post-doctoral fellowship, investigating the molecular basis underlying NF-κB activation in lymphocytes and lymphoma. In 2008, he was appointed permanent researcher by the French National Institute for Health and Medical Research INSERM. Currently, he co-leads the "Signaling in Oncogenesis, Angiogenesis, and Permeability" team at the Cancer and Immunology Research Center of Nantes, France. He has long-term experience exploring in studying cellular fate decisions in both normal and pathological conditions, with a particular focus on post-translational modifications.

Eloi Verrier is a tenured Inserm researcher and group leader at the Institute of Translational Medicine and Liver Disease in Strasbourg (Inserm U1110). He earned his PhD in 2013 from AgroParisTech, where his work focused on host–virus interactions in fish models. His research group investigates the molecular interplay between hepatotropic viruses, particularly Hepatitis B virus (HBV) and Hepatitis D virus (HDV), and hepatocyte host factors, with the goal of identifying new therapeutic targets for viral hepatitis. A major part of his work focuses on deciphering the complex interactions between these viruses and the innate immune response, with the aim of improving or replacing current IFN-based therapies. Dr Verrier has made significant contributions to the field, notably through the identification of novel host dependency factors for HDV, the development of advanced cellular models for HBV/HDV infection, and integrative transcriptomic and functional genomics approaches to understand antiviral restriction mechanisms. Beyond his research activities, Dr Verrier serves as Chair of the ANRS MIE Coordinated Action 42 (AC42), which oversees and supports fundamental and translational research on viral hepatitis across France.